Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARI-COVID: Baricitinib in COVID-19
NCT04320277Phase 3Unknown
- Sponsor
- Santo Stefano Riabilitazione
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Santo Stefano Riabilitazione. Status: unknown.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04320277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320277.